

Emmanuel S. Antonarakis, M.D.

Title:

Interrogating the AR in Advanced Prostate Cancer Using Liquid Biopsies

Abstract

The androgen receptor (AR) remains the most crucial therapeutic target for prostate cancer therapy. However, several molecular mechanisms of response and resistance to AR-targeting prostate cancer therapies have recently been elucidated. This talk will review blood-based analysis of the AR for copy-number alterations, mutations, and splicing abnormalities in an effort to understand AR-therapy response, resistance and novel therapeutic approaches.